Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Dec;36(12):625-8.

Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers

Affiliations
  • PMID: 9876998
Clinical Trial

Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers

J Teichert et al. Int J Clin Pharmacol Ther. 1998 Dec.

Abstract

Aim: The aim of the present study was to examine the pharmacokinetics of racemic alpha-lipoic acid in twelve healthy volunteers following single oral administration of 200 and 600 mg (Thioctacid 200 film tablets).

Subjects, material and methods: Each film tablet contained 200 mg of alpha-lipoic acid. In addition, an injection solution containing 200 mg of alpha-lipoic acid was administered. Plasma concentrations of alpha-lipoic acid were determined using a validated reversed-phase HPLC method with electrochemical detection having a lower limit of quantitation of 1 ng/ml. The areas under curve (AUC) were 46.82 +/- 21.46 and 157.97 +/- 35.05 microg x min/ml for the oral and intravenous administration of 200 mg, respectively.

Results: The AUC following oral administration of 600 mg was 157.83 +/- 35.82 microg x min/ml. The difference in mean t(1/2) for the two oral doses and the i.v. dose (in the range of 25.3-32.7 min) was not statistically significant.

Conclusion: The lack of a significant difference between values for apparent total plasma clearance for the 200 and 600 mg doses indicates non-saturable kinetics of alpha-lipoic acid in healthy volunteers in this dose range. The absolute bioavailability after the 200 mg dose was 29.1 +/- 10.3%.

PubMed Disclaimer

Publication types

LinkOut - more resources